| NFE2L2 |
Malignant neoplasm of skin |
disease |
Neoplastic Process |
0.32 |
DisGeNET |
| NFE2L2 |
Non-Small Cell Lung Carcinoma |
disease |
Neoplastic Process |
0.60 |
DisGeNET |
| NFE2L2 |
Squamous cell carcinoma |
disease |
Neoplastic Process |
0.37 |
DisGeNET |
| NFE2L2 |
Cholestasis |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Diabetic Nephropathy |
disease |
Disease or Syndrome |
0.37 |
DisGeNET |
| NFE2L2 |
Drug toxicity |
group |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Pathological accumulation of air in tissues |
phenotype |
Pathologic Function |
0.30 |
DisGeNET |
| NFE2L2 |
Experimental Autoimmune Encephalomyelitis |
disease |
Experimental Model of Disease |
0.30 |
DisGeNET |
| NFE2L2 |
Endometrial Neoplasms |
group |
Neoplastic Process |
0.30 |
DisGeNET |
| NFE2L2 |
Fatty Liver |
disease |
Disease or Syndrome |
0.33 |
DisGeNET |
| NFE2L2 |
Gastrointestinal Diseases |
group |
Disease or Syndrome |
0.31 |
DisGeNET |
| NFE2L2 |
Nodular glomerulosclerosis |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Heart failure |
disease |
Disease or Syndrome |
0.31 |
DisGeNET |
| NFE2L2 |
Congestive heart failure |
disease |
Disease or Syndrome |
0.31 |
DisGeNET |
| NFE2L2 |
Hepatitis, Toxic |
disease |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Hyperglycemia |
disease |
Disease or Syndrome |
0.34 |
DisGeNET |
| NFE2L2 |
Hyperplasia |
phenotype |
Pathologic Function |
0.30 |
DisGeNET |
| NFE2L2 |
Keratosis |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Keratosis Blennorrhagica |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Kidney Diseases |
group |
Disease or Syndrome |
0.32 |
DisGeNET |
| NFE2L2 |
Kidney Failure, Acute |
disease |
Disease or Syndrome |
0.50 |
DisGeNET |
| NFE2L2 |
Left-Sided Heart Failure |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Liver Cirrhosis |
disease |
Disease or Syndrome |
0.52 |
DisGeNET |
| NFE2L2 |
Liver Cirrhosis, Experimental |
disease |
Experimental Model of Disease |
0.30 |
DisGeNET |
| NFE2L2 |
Liver neoplasms |
group |
Neoplastic Process |
0.35 |
DisGeNET |
| NFE2L2 |
Necrosis |
phenotype |
Organ or Tissue Function |
0.30 |
DisGeNET |
| NFE2L2 |
Prostatic Neoplasms |
group |
Neoplastic Process |
0.30 |
DisGeNET |
| NFE2L2 |
Pulmonary Fibrosis |
disease |
Disease or Syndrome |
0.50 |
DisGeNET |
| NFE2L2 |
Skin Neoplasms |
group |
Neoplastic Process |
0.31 |
DisGeNET |
| NFE2L2 |
Adverse reaction to drug |
group |
Pathologic Function |
0.30 |
DisGeNET |
| NFE2L2 |
Ovarian Failure, Premature |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Hamman-Rich syndrome |
disease |
Disease or Syndrome |
0.31 |
DisGeNET |
| NFE2L2 |
Gonadotropin-Resistant Ovary Syndrome |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Keratoma |
phenotype |
Acquired Abnormality |
0.30 |
DisGeNET |
| NFE2L2 |
Encephalopathy, Toxic |
disease |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Adenocarcinoma of lung (disorder) |
disease |
Neoplastic Process |
0.45 |
DisGeNET |
| NFE2L2 |
Toxic Encephalitis |
disease |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Dermatitis, Allergic Contact |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Vascular System Injuries |
group |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Neurotoxicity Syndromes |
group |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Heart Failure, Right-Sided |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Fibrosis, Liver |
disease |
Disease or Syndrome |
0.36 |
DisGeNET |
| NFE2L2 |
Acute Lung Injury |
disease |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Squamous cell carcinoma of esophagus |
disease |
Neoplastic Process |
0.36 |
DisGeNET |
| NFE2L2 |
Chromosome Breaks |
phenotype |
Cell or Molecular Dysfunction |
0.30 |
DisGeNET |
| NFE2L2 |
Malignant neoplasm of liver |
disease |
Neoplastic Process |
0.31 |
DisGeNET |
| NFE2L2 |
Malignant neoplasm of prostate |
disease |
Neoplastic Process |
0.40 |
DisGeNET |
| NFE2L2 |
Chromosome Breakage |
phenotype |
Cell or Molecular Dysfunction |
0.30 |
DisGeNET |
| NFE2L2 |
Non-alcoholic Fatty Liver Disease |
disease |
Disease or Syndrome |
0.33 |
DisGeNET |
| NFE2L2 |
Endometrial Carcinoma |
disease |
Neoplastic Process |
0.31 |
DisGeNET |
| NFE2L2 |
Functional Gastrointestinal Disorders |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Carcinogenesis |
phenotype |
Neoplastic Process |
0.40 |
DisGeNET |
| NFE2L2 |
Drug-Induced Liver Disease |
disease |
Disease or Syndrome |
0.33 |
DisGeNET |
| NFE2L2 |
Carcinoma, Pancreatic Ductal |
disease |
Neoplastic Process |
0.30 |
DisGeNET |
| NFE2L2 |
Squamous cell carcinoma of the head and neck |
disease |
Neoplastic Process |
0.42 |
DisGeNET |
| NFE2L2 |
Hepatitis, Drug-Induced |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Cholera Infantum |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Acute Kidney Insufficiency |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Hyperglycemia, Postprandial |
phenotype |
Finding |
0.30 |
DisGeNET |
| NFE2L2 |
Myocardial Failure |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Heart Decompensation |
phenotype |
Pathologic Function |
0.30 |
DisGeNET |
| NFE2L2 |
Liver carcinoma |
disease |
Neoplastic Process |
0.50 |
DisGeNET |
| NFE2L2 |
Acute kidney injury |
disease |
Injury or Poisoning |
0.30 |
DisGeNET |
| NFE2L2 |
Steatohepatitis |
disease |
Disease or Syndrome |
0.34 |
DisGeNET |
| NFE2L2 |
Nonalcoholic Steatohepatitis |
disease |
Disease or Syndrome |
0.34 |
DisGeNET |
| NFE2L2 |
Hypergonadotropic Ovarian Failure, X-Linked |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Drug-Induced Acute Liver Injury |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Chemical and Drug Induced Liver Injury |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |
| NFE2L2 |
Chemically-Induced Liver Toxicity |
disease |
Disease or Syndrome |
0.30 |
DisGeNET |